ClinicalTrials.Veeva

Menu

Characterization of the Phenotypic Markers of B Cell Lymphocytes in Rheumatoid Arthritis

A

Assiut University

Status

Unknown

Conditions

Autoimmune Diseases

Treatments

Diagnostic Test: for patients and healthy donors

Study type

Observational

Funder types

Other

Identifiers

NCT03793270
17200278

Details and patient eligibility

About

Rheumatoid Arthritis (RA):

RA is a chronic inflammatory autoimmune disease that primarily affects the small joints, eventually leading to bone erosion and an inability to move (1). Several immune cells participate in the pathogenesis of RA. One of those cells is B cell.

Full description

B cell population:

B lymphocytes play several critical roles in the pathogenesis of rheumatoid arthritis. They are the source of the rheumatoid factors (RF) and anti-cyclic-citrullinated peptide (anti-CCP), which contribute to immune complex formation and complement activation in the joints (2).

There is different B cell subpopulation according to the stage of maturation and activity. Distinction of this subpopulation can be done by detection of different CD molecules expressed on cell surface (3). From all sub-population this research will focus on these immunophenotypes; immature, mature, memory and B-reg cells by using CD 19, CD24, CD38 & CD27 respectively.

Joa˜ o E. Fonseca and his team found the reduction in B cell subpopulation especially (Pre- switched memory B cells) both in RA and Arthritis in the early stage. This observation not related to using methotrexate or corticosteroid in the treatment. They used the classification of B cells with CD 19 mainly and then IgD and CD27 to identify B cells (4).

Gabriella Sármay team found that the number of B-reg CD19+ CD27+ IL-10+ cells in peripheral blood is fewer in RA patients compared with healthy controls (5).

Interleukin 10:

Interleukin (IL)-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. IL-10 mRNA levels were significantly elevated in synovial fluid mononuclear cells (SFMCs) from patients with RA compared with PBMCs peripheral blood mononuclear cells (PBMCs) from RA patients or healthy volunteers according to Isomäki P (6).

IL 10 is primarily produced by monocytes mainly and, then by lymphocytes; type 2 T helper cells (TH2), mast cells, CD4+CD25+Foxp3+ regulatory T cells, and in a certain subset of activated T cells and B cells (7).

Enrollment

90 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

  • Patient diagnosed as Rheumatoid arthritis that fulfilled ACR/EULAR Criteria (American College of Rheumatology/European League Against Rheumatism).

  • (8) Age >18 Years.

    b. Exclusion criteria:

  • Diagnosed patients with other autoimmune disease or other infections.

  • Pregnant patients.

Trial design

90 participants in 3 patient groups

patients
Description:
1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year). drugs described in the clinic.
Treatment:
Diagnostic Test: for patients and healthy donors
patients 2
Description:
2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
Treatment:
Diagnostic Test: for patients and healthy donors
healthy donors
Description:
3. Group 3: 30 healthy controls. No drugs.
Treatment:
Diagnostic Test: for patients and healthy donors

Trial contacts and locations

0

Loading...

Central trial contact

Mohamed S Badaery Ali, Prof; Khaled M Hasanein, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems